The U.S. Food and Drug Administration approved a new flu vaccine from GlaxoSmithKline called FLUARIX.
Domestic distribution of the new vaccine is scheduled to take place during the upcoming flu season. Already distributed in 79 countries outside the U.S., it will be available exclusively in Tip-Lok® syringes.
The announcement comes on the heels of a new regulation that requires long-term care facilities to offer annual flu shots.
“The shortage of flu vaccine last year was a reminder of the importance of vaccines in healthcare,” said Jean-Pierre Garnier, CEO of GlaxoSmithKline.